Gísli

@delanghelab.bsky.social @tatalab-duke.bsky.social @ipfdoc.bsky.social @kottond.bsky.social @msbr89.bsky.social @varelaslab.bsky.social @lisyvila.bsky.social @carolavoss.bsky.social Please reshare! Thank you :)

Time to stop publishing conference abstracts as AI will not distinguish quality between published abstract and published original research? @atsblueeditor.bsky.social @bmj.com

Indeed as if by magic this person/group/bot posted a heartwarming story about Ivy decontaminating mold spores. Trouble is beyond a 1993 abstract this was NEVER published in JACI, therefore heartwarming but probably wrong. DO NOT trust sources that can not be independently verified. Also…

@kaminskimed.bsky.social @kerrijohannson.bsky.social @charlottesummers.bsky.social

AI Is Inventing Academic Papers That Don't Exist -- And They're Being Cited in Real Journals Academic articles from authors using large language model are creating an ecosystem of fake research that threatens human knowledge itself.

www.rollingstone.com/culture/cult...

Is this the unavoidable endpoint when knowledge, ego and career converge? This is a chilling article which clearly needs the academic community to find a solution, but we need to rethink how we reward academic endeavour. #NoMorePublishOrPerish

Wow! As somebody who shares your rabies paranoia that is a pretty low bar for ruling out infectious causes of sudden death and harvesting lungs. 😳

Thank you so much for your hospitality @kaminskiMed. It was wonderful to interact with so many smart, talented and enthusiastic investigators and experience what an amazing environment you get to live and work in.

Oh no - now I gotta go 👔shopping! 😂 Maybe I’ll bring a tie?! 🤔😂

Would be lovely to get your perspective.

You are too kind!

Oh yes! 😂😂

One of the greatest shows on TV ever. I was particularly amused by the interpretation of the carrot and stick approach. 😂

The most exciting papers of the year! Could these observers provide insights into the potential of immunotherapy in other conditions? 🤔

This is a really great thread 🧵 about an important study using mixed methodology to understand a subject that rarely gets the attention it deserves. Kudos to the team @ucalgary.bsky.social guided by the brilliant @kerrijohannson.bsky.social

Would be fascinating to do an SR+MA on AF as co-meds in trials vs IMP in trials? 🤔

For sure there is no dose response really for Pirfenidone some dose response for nintedanib but really good point!

No, in London.

However, another study highlighting the disappearing treatment effect! Check the placebo vs Pirfenidone groups! 😳😳 we really need better drugs to #CureIPF

TETON-2 data looking good! 96ml of FVC ‘saved’ by inhaled treprostinil at 12 months. Devil will be in detail but all very promising.

YouTube video by Sky News UK immigration: What the numbers really show

youtu.be/zTs3PDEkB2w

Interesting story.
1) Brexit actually increased migration.
2) Students r source of UKs immigration‘problem’, likely due to our outstanding universities
3) Cumulative asylum seeker retention builds up
4) A ‘hostile environment’ might work but at what cost & for what impact? 😬

Pogacar vs Vingegaard?
Alcaraz vs Sinner?
Tottenham vs Arsenal?
Giants vs Dodgers?
Nemesis vs motivation?

I think this is a great idea, might be tricky to operationalise.
The current system is breaking if not already broken.
Incentivises research fraud.
Will prevent people seeing the wood because of all the dodgy trees.
#LessIsMore

This makes me sad (not altogether sure why), but I would like thank #DanielLevy for his hard work over last 25 yrs. The Stadium, European Glory Nights, Great teams, superstar players! 😍 There were some lows I’m sure but I don’t remember those. #COYS

Phenomenal result! FIRST positive 52 week study of inhaled therapy in #IPF. Benefits were independent of background therapy! 🤩
Along with Nerandomilast this shows importance of cAMP/PDE4 pathways in fibrosis & opens door 4 other therapies targeting these pathways!
#FutureLooksBright #CureIPF

Text of primary and secondary endpoints

TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁

Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD

@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

www.theglobeandmail.com/investing/ma...

There is a section on Familial Pulmonary Fibrosis, genetics & telomere length, a para on spatial transcriptomics & single cell analysis, also biomarkers. But they haven’t been used add granularity 2 classification. Whilst understandable this will eventually happen, so y rush 2 reclassify now?

Well if anybody can tell me what major paradigm shifting advance in diagnosis or pathogenesis which has substantially altered our understanding of Interstitial Lung Diseases has been included in this document I might change my mind.

I think it is as valuable and interesting as this 🤣🤣🤣

Turns out the average time from guideline to implementation is 17 years!!! (So I heard from an expert in that area!)

I think there is no clinical need to update the classification, and I just can’t wait for the next update! 🥱